Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study

Abroad (travel likely)Recruiting

Conditions

Intrahepatic Cholangiocarcinoma (Icc)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking Union Medical College Hospital (PUMCH), Beijing, China
Contact: Study coordinator (Baoluhe Zhang) · dushd@pumch.cn · 010-69152831

Study leads

Shunda Du
Principal Investigator
Peking Union Medical College Hospital (PUMCH)
Mei Guan
Principal Investigator
Peking Union Medical College Hospital (PUMCH)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Intrahepatic Cholangiocarcinoma (Icc)

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Intrahepatic Cholangiocarcinoma

Abroad (travel likely)RecruitingPHASE3

Shanghai, China

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma (Icc)

Abroad (travel likely)RecruitingPHASE2

Tianjin, China